GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » Beneish M-Score

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Beneish M-Score : -2.28 (As of May. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.28 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Aerie Pharmaceuticals's Beneish M-Score or its related term are showing as below:

AERI' s Beneish M-Score Range Over the Past 10 Years
Min: -3.84   Med: -2.38   Max: 14.21
Current: -2.28

During the past 11 years, the highest Beneish M-Score of Aerie Pharmaceuticals was 14.21. The lowest was -3.84. And the median was -2.38.


Aerie Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Aerie Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerie Pharmaceuticals Beneish M-Score Chart

Aerie Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.31 -3.29 -0.97

Aerie Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.84 -0.97 -2.13 -2.32 -2.28

Competitive Comparison of Aerie Pharmaceuticals's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerie Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Aerie Pharmaceuticals's Beneish M-Score falls into.



Aerie Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Aerie Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5571+0.528 * 0.8289+0.404 * 1.6151+0.892 * 2.0541+0.115 * 1.4878
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.461+4.679 * -0.1245-0.327 * 1.1821
=-2.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Total Receivables was $73.9 Mil.
Revenue was 36.129 + 33.311 + 29.835 + 114.666 = $213.9 Mil.
Gross Profit was 29.2 + 29.57 + 23.055 + 108.596 = $190.4 Mil.
Total Current Assets was $302.8 Mil.
Total Assets was $375.6 Mil.
Property, Plant and Equipment(Net PPE) was $71.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $20.2 Mil.
Selling, General, & Admin. Expense(SGA) was $129.6 Mil.
Total Current Liabilities was $133.3 Mil.
Long-Term Debt & Capital Lease Obligation was $332.1 Mil.
Net Income was -26.826 + -19.371 + -35.891 + 45.533 = $-36.6 Mil.
Non Operating Income was 1.049 + 0.195 + 0.023 + 1.772 = $3.0 Mil.
Cash Flow from Operations was -11.401 + -13.233 + 61.911 + -30.11 = $7.2 Mil.
Total Receivables was $64.6 Mil.
Revenue was 29.313 + 27.185 + 22.97 + 24.683 = $104.2 Mil.
Gross Profit was 21.414 + 21.008 + 16.27 + 18.149 = $76.8 Mil.
Total Current Assets was $276.0 Mil.
Total Assets was $351.8 Mil.
Property, Plant and Equipment(Net PPE) was $74.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $36.7 Mil.
Selling, General, & Admin. Expense(SGA) was $136.8 Mil.
Total Current Liabilities was $118.1 Mil.
Long-Term Debt & Capital Lease Obligation was $250.7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(73.881 / 213.941) / (64.566 / 104.151)
=0.345334 / 0.619927
=0.5571

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(76.841 / 104.151) / (190.421 / 213.941)
=0.737785 / 0.890063
=0.8289

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (302.813 + 71.056) / 375.59) / (1 - (275.952 + 74.852) / 351.802)
=0.004582 / 0.002837
=1.6151

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=213.941 / 104.151
=2.0541

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(36.688 / (36.688 + 74.852)) / (20.167 / (20.167 + 71.056))
=0.328922 / 0.221074
=1.4878

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(129.56 / 213.941) / (136.812 / 104.151)
=0.605588 / 1.313593
=0.461

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((332.113 + 133.333) / 375.59) / ((250.685 + 118.128) / 351.802)
=1.23924 / 1.048354
=1.1821

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-36.555 - 3.039 - 7.167) / 375.59
=-0.1245

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Aerie Pharmaceuticals has a M-score of -2.28 suggests that the company is unlikely to be a manipulator.


Aerie Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
Executives
Peter Frederick Lang officer: Chief Financial Officer AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese officer: Vice President of Finance AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley officer: CHRO & VP, Corp Services 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten officer: Interim CFO AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski officer: Chief Scientific Officer 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell director 2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander officer: Chief R&D Officer C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino officer: Chief Financial Officer
Vicente Jr Anido director, officer: Chief Executive Officer 1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro officer: President and COO 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Headlines

From GuruFocus

LEVIN CAPITAL STRATEGIES, L.P. Buys 1, Sells 4 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-15-2023

Aerie Pharmaceuticals Announces New Employee Inducement Grant

By Business Wire Business Wire 07-08-2022